Healthcare Spending Inches Up 3.2%

Industry: Healthcare, Healthcare & Pharma

The proposed budget for the 2023-24 fiscal year has raised concerns in the healthcare sector as there is a reduction in developmental spending, which could increase the burden on patients. The health sector allocation has been reduced to approximately 5% of the national budget, down from 5.4% in the previous fiscal year. With a total allocation of Tk 38,052 crore, the increase is only 3.22% compared to the previous year. This significant cut of Tk 3,641 crore in developmental spending under the health service division could impact healthcare delivery capacity and medicine supply.

An expert in health economics at Dhaka University expressed concerns about the potential rise in healthcare costs for patients. The budget allocated Tk 29,431 crore for the health service division, with a minor increase compared to the previous fiscal year. While operating costs have increased, the budget for development costs has been reduced. On a positive note, the budget for the Medical Education and Family Welfare Division has increased, aiming to establish new medical universities and colleges.

Source for more details:

Related News

ACI Logs Tk 13.69 Crore Loss In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

Renata Profit Falls To Tk 58 Crore In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

Square Pharma Profit Hits Tk 605 Crore In Q3 FY2024-25

May 4, 2025

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Square Pharma Directors Buy Shares Worth Tk 64.58 Crore

April 21, 2025

Two directors of Square Pharmaceuticals, Samuel S Chowdhury and Ratna Patra, each purchased 15 lakh shares, totaling Tk 64.58 crore, based on the DSE’s disclosed closing price of Tk 215.40 per share. These transactions, declared earlier in March, reflect continued confidence in the company, whose shares rose 0.05% during morning trading.

Beximco to Manage Own Firms as HC Cancels Receiver Order

March 15, 2025

The High Court (HC) has canceled its previous order to appoint a receiver for managing Beximco Group companies, allowing them to operate under their own management while being supervised by Bangladesh Bank and other regulatory bodies.

Vice Chairman of Square Pharma to Acquire 15 Lakh Shares

March 13, 2025

Ratna Patra, vice chairman and sponsor of Square Pharmaceuticals, announced her plan to purchase 15 lakh shares worth approximately Tk 33 crore at the current market price. The purchase will take place within the next 30 working days through both public and block markets on the Dhaka Stock Exchange (DSE).

Related News

ACI Logs Tk 13.69 Crore Loss In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

Renata Profit Falls To Tk 58 Crore In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

Square Pharma Profit Hits Tk 605 Crore In Q3 FY2024-25

May 4, 2025

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Square Pharma Directors Buy Shares Worth Tk 64.58 Crore

April 21, 2025

Two directors of Square Pharmaceuticals, Samuel S Chowdhury and Ratna Patra, each purchased 15 lakh shares, totaling Tk 64.58 crore, based on the DSE’s disclosed closing price of Tk 215.40 per share. These transactions, declared earlier in March, reflect continued confidence in the company, whose shares rose 0.05% during morning trading.

Beximco to Manage Own Firms as HC Cancels Receiver Order

March 15, 2025

The High Court (HC) has canceled its previous order to appoint a receiver for managing Beximco Group companies, allowing them to operate under their own management while being supervised by Bangladesh Bank and other regulatory bodies.

Vice Chairman of Square Pharma to Acquire 15 Lakh Shares

March 13, 2025

Ratna Patra, vice chairman and sponsor of Square Pharmaceuticals, announced her plan to purchase 15 lakh shares worth approximately Tk 33 crore at the current market price. The purchase will take place within the next 30 working days through both public and block markets on the Dhaka Stock Exchange (DSE).

BUSINESSMONITOR

Connect with


Dont Have Account? Please register Here